Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporatedverified

PRLD

Price:

$1.19

Market Cap:

$64.12M

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potentl...[Read more]

Industry

Biotechnology

IPO Date

2020-09-25

Stock Exchange

NASDAQ

Ticker

PRLD

The Enterprise Value as of December 2024 (TTM) for Prelude Therapeutics Incorporated (PRLD) is 71.12M

According to Prelude Therapeutics Incorporated’s latest financial reports and current stock price. The company's current Enterprise Value is 71.12M. This represents a change of -73.58% compared to the average of 269.23M of the last 4 quarters.

Prelude Therapeutics Incorporated (PRLD) Historical Enterprise Value (quarterly & annually)

How has PRLD Enterprise Value performed in the past?

The mean historical Enterprise Value of Prelude Therapeutics Incorporated over the last ten years is 938.99M. The current 71.12M Enterprise Value has changed 657.45% with respect to the historical average. Over the past ten years (40 quarters), PRLD's Enterprise Value was at its highest in in the December 2020 quarter at 2.50B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.

Quarterly (TTM)
Annual

Average

938.99M

Median

694.07M

Minimum

249.32M

Maximum

2.91B

Prelude Therapeutics Incorporated (PRLD) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Prelude Therapeutics Incorporated Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 250.33%

Maximum Annual Enterprise Value = 2.91B

Minimum Annual Increase = -80.66%

Minimum Annual Enterprise Value = 249.32M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023249.32M-3.12%
2022257.35M-54.25%
2021562.56M-80.66%
20202.91B250.33%
2019830.31M0.57%

Prelude Therapeutics Incorporated (PRLD) Average Enterprise Value

How has PRLD Enterprise Value performed in the past?

The current Enterprise Value of Prelude Therapeutics Incorporated (PRLD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

356.41M

5-year avg

961.67M

10-year avg

938.99M

Prelude Therapeutics Incorporated (PRLD) Enterprise Value vs. Peers

How is PRLD’s Enterprise Value compared to its peers?

Prelude Therapeutics Incorporated’s Enterprise Value is less than Foghorn Therapeutics Inc. (260.47M), greater than Shattuck Labs, Inc. (12.78M), less than Monte Rosa Therapeutics, Inc. (351.25M), less than Kymera Therapeutics, Inc. (2.62B), less than Nurix Therapeutics, Inc. (1.31B), less than C4 Therapeutics, Inc. (280.63M), less than Eliem Therapeutics, Inc. (0), greater than Cyteir Therapeutics, Inc. (-20511738.00), less than Rezolute, Inc. (247.14M), less than Molecular Partners AG (107.67M), less than Mineralys Therapeutics, Inc. (539.76M), greater than AN2 Therapeutics, Inc. (7.13M), less than Pharvaris N.V. (672.18M), less than PepGen Inc. (108.11M), less than TCR2 Therapeutics Inc. (79.12M), less than Revolution Medicines, Inc. (7.98B), less than Black Diamond Therapeutics, Inc. (123.50M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (33.76M),

Build a custom stock screener for Prelude Therapeutics Incorporated (PRLD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prelude Therapeutics Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prelude Therapeutics Incorporated (PRLD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prelude Therapeutics Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Prelude Therapeutics Incorporated's Enterprise Value?

What is the highest Enterprise Value for Prelude Therapeutics Incorporated (PRLD)?

What is the 3-year average Enterprise Value for Prelude Therapeutics Incorporated (PRLD)?

What is the 5-year average Enterprise Value for Prelude Therapeutics Incorporated (PRLD)?

How does the current Enterprise Value for Prelude Therapeutics Incorporated (PRLD) compare to its historical average?